Oppenheimer raised the firm’s price target on Immunocore (IMCR) to $86 from $85 and keeps an Outperform rating on the shares. The firm notes that on Wednesday, the company announced strong Q1 sales for KIMMTRAK, with revenue of $93.9M vs. OPCO/Consensus of $88M/$87M, +12% from the prior quarter.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMCR:
- Immunocore Holdings Reports Strong Q1 2025 Performance
- Immunocore price target lowered to $52 from $66 at Barclays
- Immunocore Holdings: Strong Sales Growth and Financial Position Justify Buy Rating
- Immunocore Holdings: Strong International Growth and Promising Clinical Trials Drive Buy Recommendation
- Immunocore reports Q1 EPS 10c, consensus (40c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue